Who are Normosol-R Inj's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ringer lactate (RL), Ringer-acetat, sodium bicarbonate Ringer's solution, Plasma-lyte (dynamic group), Lactated Ringer's Solution, Plasma-lyte (static group).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/normosol-r-inj.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Normosol-R Inj — Competitive Intelligence Brief

Normosol-R Inj (Normosol-R Inj) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Crystalloid intravenous fluid. Area: Critical Care / Fluid Management.

phase 3 Crystalloid intravenous fluid Critical Care / Fluid Management Small molecule Live · refreshed every 30 min

Target snapshot

Normosol-R Inj (Normosol-R Inj) — Nationwide Children's Hospital. Normosol-R is a balanced crystalloid intravenous fluid that replaces electrolytes and fluid volume to maintain physiological homeostasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Normosol-R Inj TARGET	Normosol-R Inj	Nationwide Children's Hospital	phase 3	Crystalloid intravenous fluid
Ringer lactate (RL)	Ringer lactate (RL)	Fundación Cardioinfantil Instituto de Cardiología	marketed	Crystalloid intravenous fluid
Ringer-acetat	Ringer-acetat	Rigshospitalet, Denmark	marketed	Crystalloid intravenous fluid
sodium bicarbonate Ringer's solution	sodium bicarbonate Ringer's solution	The First Affiliated Hospital with Nanjing Medical University	marketed	Crystalloid intravenous fluid / electrolyte solution
Plasma-lyte (dynamic group)	Plasma-lyte (dynamic group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution
Lactated Ringer's Solution	Lactated Ringer's Solution	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Crystalloid intravenous fluid
Plasma-lyte (static group)	Plasma-lyte (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Crystalloid intravenous fluid class)

Fayoum University Hospital · 1 drug in this class
Federal University of Juiz de Fora · 1 drug in this class
Fundación Cardioinfantil Instituto de Cardiología · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Nationwide Children's Hospital · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class
Scientific Institute San Raffaele · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Normosol-R Inj — Competitive Intelligence Brief. https://druglandscape.com/ci/normosol-r-inj. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab